An online resource created to inform healthcare professionals about advances in using gene-based testing for potential improvements in biopsy decisions and the selection of prostate cancer patients for active surveillance
This was a decision-analysis study investigating the value of PCA3 and TMPRSS2:ERG in reducing the number of unnecessary biopsies and their impact on 10-year overall survival (OS) and 15-year cancer-specific survival (CSS). Data from a multi-centre, prospectively collected cohort of 420 men who had informative urine PCA3 and TMPRSS2:ERG scores and a history of at least 1 previous negative biopsy were used. Survival estimates were derived from previous studies and a literature review.
Become a member for free! As a PCA3.org member you will be able to download the key data, contact labs, counsel your patients on biopsy decisions and publish your expert profile on the general public section.